SCHEMBL23414840

SCHEMBL23414840

COc1cc2nc(C(F)(F)F)c(Br)c(=O)n2cn1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ XBP1 P17861 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ PAX8 Q06710 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ NPM1 P06748 1/20 0.33
▸ ALK Q9UM73 1/20 0.33
▸ KDM5B Q9UGL1 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ GABRA1 P14867 1/20 0.31
▸ GABRG2 P18507 1/20 0.31
▸ GABRB3 P28472 1/20 0.31
▸ FADS1 O60427 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23456467 0.79 NPC1 (0.34) ALDH1A1NPC1LMNAGAAMAPT
SCHEMBL23414885 0.77 KDM4E (0.48) ALDH1A1GAAMAPTSMN1; SMN2KDM4E
SCHEMBL23414707 0.76 ADORA3 (0.39) —
SCHEMBL23414827 0.75 FADS1 (0.34) ALDH1A1GAAKDM4EL3MBTL1FADS1
SCHEMBL23414891 0.74 ALDH1A1 (0.39) ALDH1A1GAAKDM5BKDM4EGABRA1
SCHEMBL23456499 0.73 FADS1 (0.43) HTTKDM5BFADS1PDE10A
SCHEMBL23414877 0.72 FADS1 (0.52) ALDH1A1MAPTHTTRAB9ASMN1; SMN2
SCHEMBL23414942 0.72 FADS1 (0.54) ALDH1A1NPC1RAB9AKDM5BKDM4E
SCHEMBL23414667 0.72 GABRA1 (0.37) ALDH1A1NPC1LMNAGAAMAPT
SCHEMBL23456471 0.72 KDM4E (0.46) ALDH1A1KDM4EL3MBTL1PDE10AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473289-B2 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use AMGEN INC. (US) 2025-11-18 — — US disclosed
EP-4065579-A1 HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE Amgen Inc. (US) 2022-10-05 — — EP disclosed
US-20210171529-A1 HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE AMGEN INC. 2021-06-10 — — US disclosed
WO-2021108404-A1 HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE AMGEN INC. (US) 2021-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171529-A1 HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE SCD5, SCD, FADS2 ALDH1A1 326/4885NPC1 926/4885LMNA 1579/4885
US-12473289-B2 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use SCD5, SCD, FADS2 ALDH1A1 326/4885NPC1 926/4885LMNA 1579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback